Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders

Core Points - Aclarion, Inc. has adjourned its Annual Meeting of Stockholders originally scheduled for July 7, 2025, to July 21, 2025, to solicit additional votes on proposals [1][2] - The record date for stockholders entitled to vote remains May 9, 2025, and stockholders are encouraged to vote as soon as possible [2] - Proxies submitted for the Annual Meeting will be voted at the adjourned meeting unless revoked, and stockholders can change their votes before the meeting [3] Company Overview - Aclarion is a healthcare technology company utilizing Magnetic Resonance Spectroscopy (MRS) and a proprietary biomarker to enhance clinical treatments for low back and neck pain [5] - The company addresses a significant market, valued at $134.5 billion in the U.S. for low back and neck pain [5] - Aclarion is incorporating Artificial Intelligence (AI) to improve quality control in spectroscopy data and is researching AI applications to better associate MRS data with clinical outcomes [5]